Source: Institute for Clinical and Economic Review (ICER)
A recently released Institute for Clinical and Economic Review (ICER) evidence report assessing the comparative clinical effectiveness and value of three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine attacks found that the price of the therapies aligns with the value to patients for whom other preventive treatments have failed.
Read the report…
